Ronovo Surgical designed the Carina Platform with a modular structure to make it simply configurable. | Supply: Ronovo Surgical
Ronovo Surgical closed its Collection D financing spherical with a complete funding of $67 million. Shanghai-based Ronovo provides the $67 million to a Collection C raised earlier this yr, bringing its whole funding to greater than $100 million in 2025. On prime of that $100 million, the corporate additionally introduced in a $46 million Collection B final yr.
Johnson & Johnson’s company enterprise capital group, JJDC, led the brand new financing. With the Collection D closing, Ronovo additionally signed a focused collaboration settlement with J&J to advance its surgical robotic commercialization efforts in China. The collaboration provides hospitals in parts of China the benefits of the Carina modular robotic surgical procedure platform, together with complementary J&J MedTech surgical applied sciences.
Ronovo unveiled the Carina platform in February 2023 as a modular system constructed on proprietary know-how to allow configurable robotic help for laparoscopic surgical procedures throughout a number of specialties.
Carina addresses quite a few ache factors in minimally invasive surgical procedures. The firm says it gives surgeons with the flexibleness to decide on the very best devices and essentially the most preferrred anatomical entry. The system acquired approval from China’s Nationwide Medical Merchandise Administration (NMPA) in March 2025. This made it the primary modular surgical robotic system within the nation to acquire a first-time submitting protecting 4 main specialties (basic surgical procedure, gynecology, urology and thoracic surgical procedure), in keeping with Ronovo.
In parallel with the funding, Ronovo stated it initiated world growth efforts. It at present has submissions underway in Europe and South America.
“We’re grateful for the profitable closing of our Collection D spherical led by JJDC,” stated Dr. John Ma, Ronovo’s founder, chair, and CEO. “Carina — versatile, adaptable, and reasonably priced — embodies our dedication to democratizing entry to surgical robotics on a worldwide scale. We’re excited concerning the strategic collaboration with Johnson & Johnson MedTech, which can additional speed up our industrial momentum in China whereas laying the muse for worldwide development.”
Lilly Asia Ventures, INCE Capital, and Granite Asia additionally participated within the spherical.
Editor’s Be aware: This text was syndicated from The Robotic Report’s sibling website MassDevice.